Kopran Ltd Reports FY26 Profit of ₹25.73 Cr, Q4 Net Profit ₹18.87 Cr

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorRiya Kapoor|Published at:
Kopran Ltd Reports FY26 Profit of ₹25.73 Cr, Q4 Net Profit ₹18.87 Cr
Overview

Kopran Ltd announced its audited financial results for fiscal year 2026, reporting ₹681.42 crore in consolidated revenue and ₹25.73 crore in net profit. The company also provided an update on its planned merger with Kopran Laboratories Limited.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Kopran Ltd Announces FY26 Financial Results and Merger Update

Kopran Ltd has released its audited financial results for the fiscal year ending March 31, 2026. The company reported consolidated revenue of ₹681.42 crore and a net profit of ₹25.73 crore for the full year.

For the fourth quarter of FY 2025-26, Kopran Ltd posted revenue of ₹234.02 crore and a net profit of ₹18.87 crore.

Key Financial Highlights

The full-year performance shows a consolidated revenue of ₹681.42 crore. The company's consolidated net profit for FY26 reached ₹25.73 crore. In the final quarter of the fiscal year, revenue was ₹234.02 crore, with a net profit of ₹18.87 crore.

Merger Progress with Kopran Laboratories

Kopran Ltd provided an update on its proposed amalgamation with Kopran Laboratories Limited. Shareholder and creditor meetings are scheduled for June 3, 2026, to discuss the scheme of amalgamation. This merger, pending regulatory approvals, aims to create a more consolidated business entity.

Business Background

Kopran Ltd operates within the pharmaceutical sector, with core business segments in Active Pharmaceutical Ingredients (APIs) and Formulations. The company has been pursuing this corporate restructuring through amalgamation to streamline operations and potentially enhance shareholder value.

Forward-Looking Statements and Risks

The company cautioned that its investor presentation includes forward-looking statements. These statements are subject to risks and uncertainties that could cause actual financial results to differ from projections. Shareholders should be aware of these potential factors.

Next Steps for Investors

Investors are advised to closely follow the upcoming shareholder and creditor meetings on June 3, 2026. The subsequent approvals required from the NCLT Mumbai Bench for the amalgamation scheme will be critical indicators for the company's future structure.

Key Metrics:

  • FY 2025-26 Consolidated Revenue: ₹681.42 crore
  • FY 2025-26 Consolidated EBITDA: ₹77.90 crore
  • FY 2025-26 Consolidated Net Profit: ₹25.73 crore
  • Q4 FY 2025-26 Consolidated Revenue: ₹234.02 crore
  • Q4 FY 2025-26 Consolidated Net Profit: ₹18.87 crore

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.